Drug intelligence / Profile preview

BPR-101

Development stage: Phase 2
Lead developer: Chengdu Brilliant Pharmaceutical
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Oral, Vaginal

Overview

BPR-101 is an investigational live biotherapeutic product (LBP) developed by Chengdu Syncor Pharmaceutical Co., Ltd. for the treatment and prevention of recurrence of bacterial vaginosis (BV). It consists of specific strains of *Lactobacillus* (notably *Lactobacillus crispatus*) intended to restore and maintain a healthy vaginal microbiome. In clinical trials, BPR-101 is evaluated as an adjunct to standard antibiotic therapy, such as metronidazole. The product is unique in its administration protocol, which involves both oral and vaginal routes to ensure effective colonization and restoration of the protective lactic-acid-producing flora that inhibits the overgrowth of anaerobic pathogens associated with BV.

Beyond the preview

Go deeper on BPR-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPR-101.

Explore the full profile